USFDA Concludes Inspection with VAI Classification for Dr. Reddy's Bachupally Facility
Dr Reddys Laboratories Ltd 路 Others (Uncategorized) 路 14 Nov 2026, 10:20 pm
USFDA Concludes Inspection with VAI Classification for Dr. Reddy's Bachupally Facility Dr. Reddy鈥檚 Laboratories announced that the USFDA has classified the Good Manufacturing Practices (GMP) inspection outcome at its formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad, as Voluntary Action Indicated (VAI). Following the inspection previously disclosed on 14th Aug'26, the USFDA has officially concluded and closed the inspection under 21 CFR 20.64(d)(3), removing regulatory overhang for the manufacturing unit.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Intimation of Analyst meet 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 05 Nov 2026
- Allotment of Employee Stock options 路 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... 路 03 Nov 2026
- Transcript of Earnings call 路 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 28 Oct 2026
- Audio Recording of the Earnings call conducted on October 23, 2026 路 24 Oct 2026
